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ThermostabilityThe largest single class of drug targets is the G protein-coupled receptor (GPCR) family.Modern high-throughput
methods for drug discovery require working with pure protein, but this has been a challenge for GPCRs, and thus
the success of screening campaigns targeting soluble, catalytic protein domains has not yet been realized for
GPCRs. Therefore, most GPCR drug screening has been cell-based, whereas the strategy of choice for drug discov-
ery against soluble proteins is HTS using puriﬁed proteins coupled to structure-based drug design. While recent
developments are increasing the chances of obtaining GPCR crystal structures, the feasibility of screening directly
against puriﬁed GPCRs in the unbound state (apo-state) remains low. GPCRs exhibit low stability in detergent
micelles, especially in the apo-state, over the time periods required for performing large screens. Recentmethods
for generating detergent-stable GPCRs, however, offer the potential for researchers to manipulate GPCRs almost
like soluble enzymes, opening up new avenues for drug discovery. Here we apply cellular high-throughput
encapsulation, solubilization and screening (CHESS) to the neurotensin receptor 1 (NTS1) to generate a variant
that is stable in the apo-state when solubilized in detergents. This high stability facilitated the crystal structure
determination of this receptor and also allowed us to probe the pharmacology of detergent-solubilized, apo-
state NTS1 using robotic ligand binding assays. NTS1 is a target for the development of novel antipsychotics,
and thus CHESS-stabilized receptors represent exciting tools for drug discovery.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
GPCRs are located in the cell membranes of all human cell types
where they serve to detect and transduce extracellular signals into
intracellular signaling pathways. The GPCR gene family is the largest
in the human genome and encodes approximately 850 different recep-
tors that sense and respond to a huge variety of stimuli including neuro-
transmitters, metabolites, hormones and environmental stimuli such as
light, tastes and smells [1]. This diverse array of stimuli is a testament to
the evolutionary success of the protein architecture of GPCRs, made up
of seven transmembrane helices, which is maintained throughout the
family despite the low sequence homology. Upon activation, GPCRsP, integral membrane protein;
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).couple with and stimulate intracellular G-proteins to initiate cellular
signaling pathways.
Because of the location of GPCRs on the surface of cells and their
involvement in many, if not most, physiological pathways, GPCRs are
the major class of drug targets in the human body [2]. Conversely, less
than 10% of the GPCR family is currently targeted by prescription
drugs [2]. This discrepancy is primarily due to the lack of knowledge
about howmolecules interact with and activate GPCRs at themolecular
level, such that a true molecular design of speciﬁc agonists and antago-
nists has not been possible. Additionally, for a great number of receptors,
neither the natural ligand nor the function has been elucidated (“orphan
receptors”). Most drugs have thus come from cellular screening of the
known receptors.
Modern drug discovery techniques for targeting soluble enzymes,
for example, have higher success rates based on improved in vitro
screening assays and the parallel application of surface plasmon
resonance (SPR) or nuclear magnetic resonance spectroscopy (NMR)
based fragment screening, in conjunction with structure-based lead
optimization [3]. The hurdle for structural, mechanistic and in vitro
drug screening studies of GPCRs is that to apply a similar workﬂow to
GPCRs, the receptors must be solubilized in detergents and puriﬁed.
However, GPCRs typically exhibit low stability in detergent micelles,
especially when a sample is required to be stable in the apo-state for
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using biophysical methods.
Recent progress in obtaining crystal structures of GPCRs [4–19]
will undoubtedly aid in the computational optimization of drug leads.
Most of these structures were determined as fusion proteins, with
T4-lysozyme replacing intracellular loop 3 [5,20], which acts as a rigid
scaffold that promotes the formation of crystal contacts in lipidic-cubic
phase crystallization trials. The fusion strategy is necessary so that sufﬁ-
cient protein surface area is displayed outside of the lipid bilayer, because
for most unmodiﬁed GPCRs, virtually all of the protein is embedded
within the bilayer and thus unable to contribute to crystal contact forma-
tion. This technique does not signiﬁcantly increase the stability of the
receptor in the solubilized state [20,21] and, because the receptors are
reconstituted into insoluble media, this strategy is not useful for direct
high-throughput screening for interacting molecules. Furthermore,
such a fusion disallows interaction between the GPCR and G proteins
so that signaling as a readout is not an option.
A pioneering approach tomakingGPCRsmore accessible to structur-
al, biochemical and biophysical methods is to stabilize the receptors by
introducing thermostabilizing mutations. Stabilizing mutations have
been identiﬁed using semi-rational or alanine-scanning and screening
approaches [5,22–26], and with directed evolution methods [27–31].
Stabilized GPCRs can be successfully applied to crystallization [7,14,19,
32–35], robotic in vitro binding assays in the solubilized form [31],
and fragment screening using biophysical methods [36,37]. Generally,
these studies require the receptor to be puriﬁed in the presence of a li-
gand to stabilize the receptors during the time needed for puriﬁcation
and assay setup. This necessitates extensive washing to remove bound
ligand before assays can be conducted [36], and the instability of these re-
ceptors in the apo-statemay limit the time that samples can be probed to
unrealistically short intervals. To enable reliable measurements of GPCR
samples over the time scales required for high-throughput screening
(HTS) assays or NMR-based fragment screening, receptors are required
that are stable for many hours, preferably in the apo-state. Here we use
the cellular high-throughput encapsulation, solubilization and screening
(CHESS) method to evolve neurotensin receptor 1 (NTS1) mutants that
meet these requirements. The crystal structure of one of the resultant
receptors was recently solved in a detergent-solubilized form [19]. Here
we demonstrate that the long-term, apo-state stability of these CHESS-
stabilized NTS1 variants makes them suited to HTS-compatible ligand
binding assays using isolated receptors in detergent micelles.
2. Materials and methods
2.1. Stabilization of NTS1 using CHESS
Escherichia coli strain DH5α was transformed with the StEPM303
library and receptor expression was induced as described previously
[29,31]. 1.75 × 1010 cells from the expression culture were encapsulated
with one layer of chitosan and 1 layer of alginate as described previously
[31]. For the initial selection round, the capsule population was exposed
to PBS pH 7.4, 1 mM EDTA and 1.7% DM (termed PBS-E(DM)) for 3 h at
20 °C with vigorous shaking without ligand, followed by 2 h at 20 °C in
the presence of 20 nM BODIPY FL-labeled NT(8–13) (FL-NT). Capsules
were washed twice in PBS-E(DM) and subjected to FACS using a
FACSAria III cell sorter (BD Biosciences). Capsules exhibiting the top
0.5–1% of ﬂuorescence of the population were retained, resulting in the
collection of 50,000 capsules. Genetic information was recovered from
sorted capsules by PCR ampliﬁcation using NTS1-speciﬁc primers after
incubation in an ultrasonic water bath for 5 min. For the second round
of selection, the ampliﬁed receptor genes were re-cloned, proteins
expressed and the cells encapsulated as above. The capsule population
was ﬁrst treated with PBS-E(DM) for 3 h at 20 °C, followed by addition
of 20 nM FL-NT for 1 h at 20 °C, before the capsules were collected by
centrifugation and resuspended in PBS-E containing 2% octyl-β-D-
glucopyranoside (OG) (PBS-E(OG)) and 20 nM FL-NT at 4 °C. Capsuleswere washed once in 20 nM FL-NT in PBS-E(OG) to promote efﬁcient
detergent exchange before being incubated for 2 h in PBS-E(OG) with li-
gand at 4 °C. Capsuleswerewashed twice in PBS-E(OG) and subjected to
FACS as above, resulting in the collection of 38,000 capsules. These clones
were isolated and re-cloned as above for a third round of selection. In the
third round of selection, the capsules were exposed to PBS-E(DM) for 3 h
at 20 °C, followed by the addition of 20 nM FL-NT for 1 h at 20 °C, before
the capsules were collected by centrifugation and resuspended in PBS-E
containing 2% heptyl-β-D-thioglucopyranoside (HTG) (PBS-E(HTG))
and 20 nM FL-NT at 4 °C. Capsules were washed once in 20 nM FL-NT
in PBS-E(HTG) to promote efﬁcient detergent exchange before being in-
cubated for 25 h at 4 °C. After this step, capsules were washed twice in
PBS-E(HTG) and sorted with FACS as above, resulting in the collection
of 20,000 capsules. The DNA encoding these clones was isolated and
re-cloned into an expression vector containing a C-terminal sfGFP fusion,
as in [31]. The CHESS workﬂow is depicted in Fig. 1.
2.2. Stability analysis of 96 individual NTS1 variants from the selected
population
Forty-seven individual colonies derived from the capsules sorted in
the 3rd round of CHESS (Section 2.2) were picked and used to inoculate
1.2 ml cultures of LB broth containing 100 μg/ml ampicillin and 1% glu-
cose in a 96-deep-well plate. As a control, a colony of cells transformed
with a previously stabilized NTS1 variant (C7E02) [29] was also picked.
Cultures were grown for 16 h at 37 °C before being used to inoculate 48,
5-ml-expression cultures in 24-deep-well plates. Receptors were
expressed as described previously at 20 °C for 20 h [31]. The initial cul-
tures were centrifuged and the plasmid DNA isolated. After expression,
cell pellets were solubilized in 1 ml PBS-E(DM) for 2 h at 20 °C and the
cell debris pelleted with centrifugation at 5000 g for 20 min. 0.8 ml of
the supernatant was transferred to a 96-well KingFisher plate (Thermo
Scientiﬁc) containing 20 μg of streptavidin T1 Dynabeads (Life Technol-
ogies) per well. Samples were then robotically manipulated using a
KingFisher Flex robot (Thermo Scientiﬁc) as described previously [31],
including binding of 20 nM HL-NT for 1 h, exchanging the detergent
to 2%HTG for 1.5 h,washing away unbound ligand for 5min and eluting
the beads into 0.25ml PBS-E(HTG) for the analysis of ligand binding in a
ﬂuorescent plate reader (Tecan M1000) and with ﬂow cytometry
(Partec CyFlow Space). 100,000 beads from the binding assay were
measured with ﬂow cytometry, with the average ﬂuorescence intensity
of single-sized beads presented in Fig. 2B upon 638 nm laser excitation
and emission at 675 nm (20 nm bandpass).
2.3. Construct optimization
Based on the stability screen, the most promising stabilized variant,
number 47 (termed NTS1-H4) was sequenced. Before further analysis
with ﬂuorescent binding assays, the following changes were made to
the receptor. A mutation in the conserved E/DRY motif was reverted
(L167R), a potential human rhinovirus 3C protease site was removed
from intracellular loop 3 (Q274A), alanine 342 in extracellular loop 3
was reverted to the naturally occurring phenylalanine (A342F) and all
exposed cysteines were mutated to either alanine or serine (C278A,
C386A, C388A, C417S) for allowing the future introduction of unique
cysteines. The resultant receptor was termed NTS1-H4(BM1) and the
encoding gene was synthesized by Genscript.
2.4. Stability comparison of engineered NTS1 variants
Stability measurements of selected NTS1 receptor variants were
performed as described previously [28,31]. NTS1 receptor variants
were expressed with a C-terminal sfGFP-Avi-tag fusion. A cell pellet
corresponding to a 2.5 ml expression culture was used for one single
measurement reporting functionally folded receptor as determined by
a ligand binding assay. Receptors were solubilized in solubilization
Fig. 1. CHESS-based selection workﬂow for generating NTS1 mutants that were resistant to short-chain detergents, apo-state solubilization and long term incubations in the solubilized
state. CHESS rounds are indicated by R1-3. For a diagrammatic representation of the CHESS method, see Scott and Plückthun [31].
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CHS, 1 mM EDTA, complete protease inhibitors (Roche), 40 μg/ml
deoxyribonuclease I (Roche), 1 mg/ml lysozyme). Solubilization was
performed at 4 °C for 2 h. Cell debris was removed by centrifugation
and the supernatant was exposed to streptavidin-coated paramagnetic
beads. Solubilized receptor variants were allowed to bind to the beadsFig. 2. Single-clone analysis of 47 selected NTS1 mutants after 3 rounds of CHESS. Detergent-so
The ability of the receptor-coated beads to speciﬁcally bind HL-NT after 2 h (open columns) or 9
plate reader (A), or an analytical cytometer (B). Clone 47, indicated with arrows, was termed Nfor 1 h at 4 °C before being transferred in 96-well plates for subsequent
manipulation with a KingFisher Flex magnetic particle processor.
Receptor-coated beads were subjected to detergent solution, PBS-
E(DCC) (PBS pH 7.4, 1 mM EDTA, 1% (w/v) DDM, 0.5% (w/v) CHAPS,
0.1% (w/v) CHS) with or without 20 nMHilyte-647 labeled neurotensin
8–13 (HL647-NT). Non-speciﬁc binding was determined by addinglubilized, biotinylated receptors were captured onto streptavidin-coated magnetic beads.
8 h (striped columns) in the short-chain detergent HTGwasmeasured using a ﬂuorescent
TS1-H4.
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After a further 0 h or 18 h exposure to DDM, beads were washed
twice with PBS-E(DCC) and those exposed to detergent in the unbound
state were transferred to solutions containing 20 nMHL647-NTwith or
without competitor for 1.5 h. Receptor-coated beads were washed
twice in PBS-E(DCC) and transferred to black 96-well microplates
(Greiner) in a ﬁnal volume of 100 μl. HL647-NT and sfGFP ﬂuorescence
levels were measured in each well using an M1000 dual monochroma-
tor ﬂuorescence plate reader (Tecan) with excitation at 630 nm for
HL647-NT and 488 nm for sfGFP. Fluorescence emission for HL647-NT
was measured at 680 nm and for sfGFP at 530 nm.
Thermal stability measurements in PBS-E(DCC) of NTS1 receptor
variants were essentially performed as described for the analysis of
detergent stability (see above). After exposure of solubilized receptor
variants to streptavidin-coated paramagnetic beads, receptor-coated
beadswere resuspended in PBS-E(DCC)with orwithout ligand (or com-
petitor). Beads were transferred to 96-well PCR plates and exposed to
different temperatures for 30 min in a gradient PCR cycler (Biometra).
After heat treatment, receptor-coated beads that were heated in the
absence of ligand were incubated with PBS-E(DCC) containing 20 nM
HL647-NT or competitor for 1.5 h. Beads were washed twice in PBS-
E(DCC) and transferred to black 96-well microplates and ﬂuorescence
intensities of HL647-NT and sfGFP in each well were determined as
above. The data were analyzed by nonlinear regression ﬁtting with
GraphPad Prism.
2.5. KingFisher saturation binding assays
NTS1-H4(BM1) was expressed in 400 ml cultures for 20–24 h at
20 °C, the cells harvested with centrifugation and the pellet resuspend-
ed in 10 ml 50 mM HEPES (pH 7.8) containing 200 mM NaCl, 10 mM
EDTA, 1 mg/ml chicken lysozyme, 10 U/ml DNAse, 1.7% DM and 0.5%
CHAPS. Cells were solubilized at 20 °C with vigorous shaking for 3 h.
Cell debris was removed with centrifugation at 15,000 g for 10 min at
4 °C. The supernatant containing solubilized receptor was then incubat-
ed with streptavidin-coated paramagnetic beads, 2.5 μg of beads per ml
of culture, at 4 °C for 1 h to immobilize the biotinylated receptor
onto the beads. Beads were collected with centrifugation at 5,000 g
for 5 min and resuspended in assay buffer (50 mM HEPES (pH 7.8),
200 mM NaCl, 10 mM EDTA and 0.1% DM) at a ﬁnal concentration of
100 μg beads per ml. 20 μg of beads were then added to 48 wells of a
deep well KingFisher plate (plate #1) (Thermo Scientiﬁc). A concentra-
tion series of Alexa-647 labeled neurotensin 8–13 (A647-NT)wasmade
in assay buffer and 1 ml of each added to several wells of a separate
KingFisher plate (plate #2). For each A647-NT concentration, a separate
solution wasmade containing an excess of unlabeled neurotensin 8–13
(10 μM),with 1ml of each being aliquoted into designatedwells of plate
#2. 200 μl and 100 μl of assay buffer were added to 48 wells of another
two KingFisher plates, plate #3 and plate #4 respectively. A KingFisher
96 magnetic particle processor was used to automatically perform the
following steps at 4 °C: the beads were captured from plate #1 and
transferred to plate #2, beads and ligand solutions were mixed for 2 h
at 4 °C, and beads were transferred to plate #3 and washed for
1.5 min before being transferred to plate #4. Beads were transferred
with a multichannel pipette from KingFisher plate 4 to a Greiner non-
binding black 96-well plate. The sfGFP (excitation ﬁlter 485 nm, band
pass 12 nm, emission ﬁlter 520 nm, band pass 10 nm) and Alexa-647
(excitation ﬁlter 640 nm, band pass 10 nm, emission ﬁlter 670 nm,
band pass 10 nm) signals from each well were measured using an
Omega Polarstar plate reader (BMG Labtech). To determine if ligand
depletion was occurring during the binding incubation, 50 μl of the
A647-NT solutions in KingFisher plate #2 was transferred to a Greiner
non-binding ﬂuorescence 96-well plate and the Alexa-647 signals of
the wells compared. Data were analyzed with GraphPad Prism,
with curves ﬁtted using the one site — total and nonspeciﬁc binding
equations.2.6. KingFisher competition binding assays
Receptor-coated bead samples were prepared and aliquoted into
KingFisher plate #1 as described in Section 2.5. In plate #2, concentra-
tion series of the various competitors were added, all in assay buffer
supplementedwith 2 nMA647-NT, 0.5ml perwell. Competitors includ-
ed SR 48692 (Tocris Biosciences and Sigma Aldrich), SR 142948 (Tocris
Biosciences), neurotensin 8–13 (Sigma Aldrich) and neurotensin 1–12
(synthesized by GL Biochem, Shanghai, China). The binding assays
were performed using a KingFisher 96 robot and Omega Polarstar
plate reader as in Section 2.5. Data were analyzed using GraphPad
Prism with curves ﬁtted using the one site — ﬁt Ki equation. Data from
3 separate experiments were pooled and the estimated Kd values for
A647-NT calculated in Section 2.5 were used to ﬁt the competition
curves.
3. Results
3.1. CHESS based evolution of apo-state stable NTS1 variants
To evolve anNTS1 variant that could bepuriﬁed in short-chain deter-
gents for X-ray crystallization and exhibit apo-state and long-term
stability in the solubilized form, we used the highly diverse StEPM303
library of NTS1 mutants and selected using CHESS, following the strate-
gy outlined in Fig. 1. In each selection round, the encapsulated GPCRs
were solubilized for 3 h, at 20 °C, in the absence of ligand to place selec-
tive pressure on apo-state stability. In the second and third rounds of
selection, the encapsulated receptor population was exposed to the
short-chain detergents OG and HTG, respectively, placing selective
pressure on the population for stability in detergents that are suitable
for vapor diffusion crystallization of GPCRs. Finally, the long-term stabil-
ity was selected for by leaving the third generation of the evolving
population of GPCRs in HTG for 25 h before selecting out themost stable
clones with FACS.
3.2. Isolating NTS1-H4 from the CHESS selected population
The genes encoding the CHESS-selected NTS1 variants were isolated
from the sorted capsules and cloned into an expression vector compris-
ing C-terminal sfGFP and avi-tag (for in vivo biotinylation) fusions.
Unlike GFP, sfGFP folds rapidly into a highly stable ﬂuorescent protein
that does not act as a folding reporter, but rather as a measure of total
protein concentration [38]. The stability of 47 receptor variants was
assayed by testing their ability to bind a ﬂuorescently labeled
neurotensin ligand after solubilization in HTG for 2 h and 98 h (Fig. 2).
In this assay, solubilized receptors were captured on streptavidin-
coated beads and exposed to ﬂuorescently labeled neurotensin 8–13
(HL-NT). The ability of each clone to bind ligand at the given time points
was determined by washing the beads and measuring the amount of
HL-NT bound to the beads with a ﬂuorescent plate reader (Fig. 2A)
and a ﬂow cytometer (Fig. 2B). Of these receptors, clone 47 (NTS1-H4)
was selected for further analysis because of its ability to bind high levels
of NT after 2 h and 98 h solubilized in HTG, when measured with both
methods.
3.3. Comparison of the stability of NTS1-H4 to other NTS1 variants
To determine whether NTS1-H4 exhibited favorable long-term and
apo-state stability, we compared the stability of this receptor to three
other variants: (i)wild-type rat NTS1, (ii) a thermostabilized variant pro-
duced through systematic mutation by Shibata et al. [26] (NTS1-7m),
and (iii) a highly optimized variant generated through evolution
using bacterial display and systematic mutation by Schlinkmann et al.
(TM86V) [29,31]. Each receptor was expressed in E. coli with an sfGFP-
avi-tag C-terminal fusion, resulting in the production of ﬂuorescent,
biotinylated receptor. Unmodiﬁed NTS1 is not stable in detergents such
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variants, we solubilized the cells in a mild detergent mix (PBS-E(DCC)).
Solubilized receptors were immobilized on streptavidin-coated beads
and subjected to a range of temperatures for 30 min in the presence
(Fig. 3A) or absence (Fig. 3B) ofﬂuorescently labeled neurotensin to gen-
erate thermostability curves. Such curves are commonly used to rank the
stabilities of engineered GPCRs, and the temperature at which only half
the receptor proteins are able to bind ligand is referred to as the apparent
melting temperature (Tm). NTS1-H4 exhibited the highest thermostabil-
ity of all the variantswhenheated in both the presence (Tm=57 °C) and
absence (Tm = 48.1 °C) of excess neurotensin (Fig. 3A–B). Thus, the
thermostability of NTS1-H4 in this harsh detergent is improved by 21.6
°C in the bound state and 26.8 °C in the apo-state compared to unmodi-
ﬁed NTS1.Fig. 3. The stabilities of thermostabilized NTS1mutants generated using different methods
were compared towild typeNTS1. The thermostabilities ofwild-type rat NTS1 (NTS1, ﬁlled
circleswith dotted lines), NTS1-7m (ﬁlled squareswith solid lines), TM86V (ﬁlled triangles
with dashed lines) and NTS1-H4 (crosses with solid lines) weremeasuredwith the recep-
tors heated in the presence of HL-NT (A) or in the apo-state (B). To allow WT to be ana-
lyzed as well, the experiment was carried out in DDM/CHAPS/CHS. Apparent melting
temperatures (Tm) were determined with non-linear regression and are displayed in
parentheses next to the ﬁgure keys. (C) Long-term stability of the 4 receptorswas assayed
bymeasuring the relative levels of HL-NT binding 3 h after solubilization (ﬁlled columns),
21 h after solubilization, and 18 h of which the receptors were incubated with HL-NT
(open columns), or 21 h after solubilization incubated in the apo-state (checkered
columns). The receptors were incubated at 4 °C.The relative amount of folded receptor in each of the samples was
monitored after 3 h in the apo-state and either 21 h in the apo-state
or with HL-NT bound at 4 °C. The relative levels of folded receptor
were calculated by measuring the ratio of bound HL-NT ﬂuorescence
(level of folded protein) to the sfGFP ﬂuorescence (total protein) in
each sample at various time points. As expected, unmodiﬁed NTS1
displayed the lowest level of folded receptor under each condition,
closely followed by NTS1-7m (Fig. 3C). Interestingly, for all the receptor
samples, there was no signiﬁcant difference in the relative NT binding
levels after a 21 h incubation at 4 °C in the presence of HL-NT. There
was a striking difference, however, when the solubilized receptors
were incubated for 21 h at 4 °C in the absence of NT (Fig. 3C). Under
these conditions, no binding of NT could be detected on NTS1, while
NT binding to NTS1-7m and TM86V was decreased by 72% and 63%
respectively, whereas only a 22% decrease in ligand binding was seen
for NTS1-H4.
3.4. Saturation binding of NT to solubilized NTS1-H4
The high stability exhibited by NTS1-H4 in the apo-state indicated
that this variant could be used to probe the binding of ligands to solubi-
lized, isolated receptor preparations in a low-cost high-throughput
compatible way. To demonstrate this, we expressed and captured
NTS1-H4-sfGFP onto magnetic beads and using a KingFisher magnetic
particle processor and ﬂuorescent plate reader, conducted saturation
binding assays using Alexa647-NT (Fig. 4A). The ligand binding step
was conducted for 2 h at 4 °C in 1 ml of solution, which resulted in no
signiﬁcant ligand depletion, even at only 100 pM A647-NT (Fig. 4B).
Non-speciﬁc binding was determined by measuring the binding of in-
creasing concentrations of A647-NT in the presence of 1 μM unlabeled
NT8-13. To control for differences in bead loading, sfGFP ﬂuorescence
was measured in each well and the speciﬁc binding was calculated as
a ratio of A647-NT ﬂuorescence to sfGFP ﬂuorescence. Fitting the resul-
tant data enabled us to estimate the Kd of A647-NT binding to NTS1-H4
at 0.65 ± 0.13 nM.
3.5. Competition binding assays using solubilized NTS1-H4
To probe the binding of unlabeled ligands to solubilized NTS1-H4,
competition binding assays were performed in the same robotic
manner, using 2 nM A647-NT as the labeled ligand (Fig. 4C). Unlabeled
agonists neurotensin 8–13 (NT8-13) and neurotensin 1–12 (NT1-12),
along with antagonists, SR48692 and SR142948, were allowed to
compete with A647-NT in a dose-dependent manner (Fig. 4C). Using
the estimated Kd value for A647-NT (Section 3.4), from the competition
binding experiments we were able to ﬁt Ki values for NT8-13, NT1-12,
SR48692 and SR142948, respectively (Table 1).
3.6. Sequence of NTS1-H4
NTS1-H4was sequenced and found to contain 25 amino acid substi-
tutions over wild-type rat NTS1 including; S83G, A86L, T101R, H103D,
H105Y, L119F, M121L, E124D, R143K, D150E, A161V, R167L, R213L,
V234L, K235R, V240L, I253A, I260A, N262R, K263R, H305R, C332V,
T354S, F358V, and S362A. Of these, H103D, H105Y, A161V, R213L,
V234L, H305R and S362A are derived from the parental receptor in
the StEPM303 library (NTS1–DO3) and thus the other 18 mutations
were acquired during the selection outlined in Fig. 1. Fig. 5 indicates
the positions of these mutations on the crystal structure of NTS1-H4
[19].
4. Discussion
The critical advantage of CHESS over other techniques is that
millions of GPCR-mutant-containing microcapsules can be screened di-
rectly for the desired stability properties within an hour by using FACS.
Fig. 4. Saturation (A–B) and competition (C) binding assays were performed on solubi-
lized, biotinylated and sfGFP tagged NTS1-H4, immobilized on streptavidin-coated
magnetic beads. For saturation binding (A), beads were exposed to increasing concentra-
tions of A647-NT in the presence of excess NT8-13 (COMPETITION, open triangles,
dashed line) or without competition (TOTAL BINDING, open circles, solid line). The ratio
of A647-NT to sfGFP ﬂuorescence was measured to account for slight differences in bead
concentrations across the 96-well plates. (B) Potential ligand depletion was assayed by
measuring the levels of A647-NT retained in the bindingwells from (A) upon the removal
of the receptor-coated beads. A decrease in A647-NT in the total binding wells (black
columns) compared to the competition wells (checkered columns), where unlabeled NT
would saturate the receptor and thus no ligand can be removed, would indicate depletion
of A647-NT in the binding step. No ligand depletion was observed. For competition
binding (C), NTS1-H4 coated beads were exposed to 2 nM A647-NT and increasing
concentrations of unlabeled NT8-13 (ﬁlled circles with solid line), NT1-12 (open circle
with dashed line), SR48692 (ﬁlled triangles and solid line) and SR142948 (open squares
with dotted line). The ratio of A647-NT to sfGFP ﬂuorescence was measured, with the
data sets normalized to 100% based on theﬂuorescence of wells containing no competitor.
Mean values± the standard error of the mean (SEM) are plotted from data pooled across
3 separate experiments.
Table 1
Binding constants derived from competition binding experiments using solubilizedNTS1-H4.
Ligand Fitted constant nM SEM Figure
NT8-13 Ki 0.34 0.09 Fig. 4C
NT1-12 Ki 306 77 Fig. 4C
SR48692 Ki 87 27 Fig. 4C
SR142948 Ki 0.5 0.1 Fig. 4C
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stable in short-chain detergents that are desirable for crystallization. In
addition,we selected for stability over 24 h in such detergents, aswell as
receptors that are exhibiting apo-state stability. We believe such prop-
erties to be highly desirable for the application of the experimental
methods commonly used for structure-based drug design.The encapsulated cells were resistant to HTG over these time pe-
riods, and genes encoding highly stable NTS1 mutants could be isolated
from the sorted capsules that exhibited high ﬂuorescent ligand binding
(Fig. 2). The clone thatwas able to bind themost ﬂuorescent ligand after
2 h and 98 h solubilized in HTG, when measured using 2 different in-
struments, was termedNTS1-H4. NTS1-H4 exhibited all of theproperties
we were seeking, including high thermostability when heated in the
presence and absence of ligand (Fig. 3A–B), and long-term, apo-state
stability in detergent (Fig. 3C).
Because NTS1 has been stabilized using several methods, we were
able to directly compare the resultant receptors with the wild-type
protein. NTS1-7m was stabilized using the systematic mutagenesis
approach [26] and TM86Vwas derived through a combination of evolu-
tionwith bacterial display for high expression and systematicmutagen-
esis [29]. Using a detergent mixture known to maintain unmodiﬁed
rNTS1 in a stable state under mild conditions [39,40], thermostability
assays were performed on the 4 receptors (Fig. 3A-B). When heated in
both the presence and absence of ligand, NTS1-H4 was the most ther-
mostable, followed by TM86V, NTS1-7m and wild type. Compared to
rNTS1, NTS1-H4 exhibited 21.6 °C and 26.8 °C improvement in thermo-
stability when heated in the bound and apo-state respectively, themost
stable by over 10 °C. NTS1-H4 also exhibited the highest stability of the
4 receptorswhen incubated in detergent for over 21h in the presence or
absence of bound ligand (Fig. 3C).
This high level of apo-state stability meant that we could successful-
ly use bacterially expressed NTS1-H4, captured onto magnetic beads, in
robotic ﬂuorescence-based saturation and competition binding assays
(Fig. 4). From ﬁtting the saturation binding curves the Kd of the ﬂuores-
cently labeled neurotensin analogue, Alexa-647-labeled neurotensin
8–13 (A647-NT), could be estimated to be 0.65 nM± 0.13, which com-
pares well to Ki values reported for unlabeled versions of this peptide
using NTS1 expressing cells and tissues [41]. The high signal-to-noise
ratio in the saturation binding assays using this labeled peptide enabled
us to conduct competition binding assays using a sub-saturating con-
centration of A647-NT (2 nM). Ki values for the binding of unlabeled
NT8-13, NT1-12, SR48692 and SR142948 to NTS1-H4 were calculated
from the resultant curves (Fig. 4C and Table 1). Calculated Ki values
compared well to the literature values for NT8-13 [41], NT1-12 [42]
and SR142948 [43], where cell culture and tissue preparations were
used for NTS1 competition binding assays. This demonstrated that our
engineered, bacterially expressed and detergent-solubilized GPCR
exhibited native-like ligand binding behavior.
Interestingly, the antagonist SR48692 was less potent at competing
A647-NT binding to solubilized NTS1-H4, compared to WT NTS1
(which could only be tested in cell-based binding studies), by a factor
between 2.7 and 44 fold, depending on the values cited in the literature
[43–45]. The afﬁnity of SR48692 to the thermostabilized NTS1 variant
NTS1-GW5 was reduced even by 130–200 fold when measured in
insect cell membranes, whereas binding of the agonist to this receptor
was unaltered [14]. This points to a mutation that may reduce antago-
nist afﬁnity compared to agonist afﬁnity, even though a small inﬂuence
of solubilization cannot be excluded.
NTS1-H4 andNTS1-GW5 share only one homologous stabilizingmu-
tation at position 358 in TM7, which is a substitution from Phe to Ala in
NTS1-GW5 and to Val in NTS1-H4. Mutation of this position to alanine
has been reported to reduce the afﬁnity of SR48692 for NTS1 but not
that of neurotensin [45] and result in a constitutively active receptor
Fig. 5.Positions of CHESS-selectedmutations in the crystal structure ofNTS1-H4 (PDB ID: 4BWB)displayed at two angles rotated by90°. TM1 is colored darkblue, TM2 light blue, TM3cyan,
TM4 green, TM5 yellow, TM6 orange,TM7 red and neurotensin purple.
2823D.J. Scott et al. / Biochimica et Biophysica Acta 1838 (2014) 2817–2824with respect to inositol phosphate production [46], suggesting that the
lower afﬁnity of SR48692 for both NTS1-H4 and NTS1-GW5may be a re-
sult of themutation at position 358. Overall, engineering NTS1-H4 to be
detergent-stable in the apo-state has enabled us to pharmacologically
characterize the orthosteric binding site of a detergent-solubilized
GPCR using low cost, high-throughput compatible assays.
Thermostabilization of NTS1 has so far resulted in the determination
of 5 structures of different receptor variants or constructs. NTS1-GW5
was engineered using systematic mutagenesis [47], and the crystal
structure of this receptor, produced in insect cells, was determined
using the T4-lysozyme fusion and lipidic cubic phase crystallization
approach [14]. The crystal structures of two NTS1–TM86V constructs,
derived from directed evolution using bacterial display [29], were re-
cently solved in detergent using vapor diffusion crystallization [19]
without any fusion to another protein. In the same study, the structures
of two more receptors were determined, NTS1-G7 [31] and NTS1-H4
(engineered in this manuscript), which were stabilized using CHESS.
Of note is that the structures of NTS1–TM86V, NTS1-G7 and NTS1-H4
were the ﬁrst GPCR structures solved from bacterially expressed
protein. Furthermore, the direct selection of NTS1-G7 and NTS1-H4 for
stability in short-chain detergents allowed these receptors to be crystal-
lized in short-chain detergents using vapor diffusion crystallography
without any systematic mutational optimization.
A thorough comparison of the 5 structures can be found in Egloff
et al. [19]. While NTS1-H4 is the most thermostable variant described
to date, it also contains themost mutations. In Fig. 5, the CHESS selected
mutations in NTS1-H4 are highlighted in the crystal structure. Selected
mutationswere relatively evenly distributed across transmembrane do-
mains (TMs) 1–3 and TMs 5–7, with the most mutations occurring in
TM5 (6 substitutions) (Fig. 5). NTS1-7m, NTS1-GW5, TM86V, NTS1-G7
and NTS1-H4 only share homologous stabilizing mutations at positions86 (A86L) and 358 (F358A or V), indicating that stabilization can be
achieved through a variety of mutational modes.
In addition to structure determination, puriﬁed thermostabilized
GPCRs have also proven to be useful tools for biophysical analysis of
ligand binding and fragment screening [36,37,48]. For these types of
studies it is highly beneﬁcial to have apo-receptor samples that are
stable in detergents over the long timeperiods needed tomeasure bind-
ing kinetics, and that will not denature upon ligand dissociation. The
engineering of NTS1-H4 is a demonstration of the utility of CHESS for
evolving receptors with the properties needed to conduct biochemical
and biophysical experiments on solubilized, puriﬁed GPCRs.
Acknowledgements
We acknowledge the professional help given by the staff of the
Center for Microscopy and Image Analysis at the University of Zurich,
where all FACS was performed, particularly Vinko Tosevski and Claudia
Dumrese. Natasha Lam, The Florey Institute, is acknowledged for her
assistance in conducting the saturation and competition binding assays.
Thisworkwas supported by a C. J.Martin Biomedical Overseas Fellowship
(520309) from the National Health and Medical Research Council of
Australia and a postdoctoral fellowship from the Forschungskredit of
the University of Zurich (both to D.J.S.). This project was funded by the
Swiss National Science Foundation NCCR Structural Biology 51NF40-
117226 and subsequent grant 31003A_153143 (both to AP).
References
[1] R. Fredriksson, H.B. Schiöth, The repertoire of G-protein-coupled receptors in fully
sequenced genomes, Mol. Pharmacol. 67 (2005) 1414–1425.
[2] J.P. Overington, B. Al-Lazikani, A.L. Hopkins, How many drug targets are there? Nat.
Rev. Drug Discov. 5 (2006) 993–996.
2824 D.J. Scott et al. / Biochimica et Biophysica Acta 1838 (2014) 2817–2824[3] J.S. Mason, A. Bortolato, M. Congreve, F.H. Marshall, New insights from structural
biology into the druggability of G protein-coupled receptors, Trends Pharmacol.
Sci. 33 (2012) 249–260.
[4] K. Palczewski, T. Kumasaka, T. Hori, C.A. Behnke, H. Motoshima, B.A. Fox, I. Le Trong,
D.C. Teller, T. Okada, R.E. Stenkamp, M. Yamamoto, M. Miyano, Crystal structure of
rhodopsin: a G protein-coupled receptor, Science 289 (2000) 739–745.
[5] V. Cherezov, D.M. Rosenbaum, M.A. Hanson, S.G. Rasmussen, F.S. Thian, T.S. Kobilka,
H.J. Choi, P. Kuhn, W.I. Weis, B.K. Kobilka, R.C. Stevens, High-resolution crystal
structure of an engineered human beta2-adrenergic G protein-coupled receptor,
Science 318 (2007) 1258–1265.
[6] V.P. Jaakola, M.T. Grifﬁth, M.A. Hanson, V. Cherezov, E.Y. Chien, J.R. Lane, A.P.
Ijzerman, R.C. Stevens, The 2.6 Ångström crystal structure of a human A2A
adenosine receptor bound to an antagonist, Science 322 (2008) 1211–1217.
[7] T. Warne, M.J. Serrano-Vega, J.G. Baker, R. Moukhametzianov, P.C. Edwards, R.
Henderson, A.G. Leslie, C.G. Tate, G.F. Schertler, Structure of a beta1-adrenergic G-
protein-coupled receptor, Nature 454 (2008) 486–491.
[8] E.Y. Chien, W. Liu, Q. Zhao, V. Katritch, G.W. Han, M.A. Hanson, L. Shi, A.H. Newman,
J.A. Javitch, V. Cherezov, R.C. Stevens, Structure of the human dopamine D3 receptor
in complex with a D2/D3 selective antagonist, Science 330 (2010) 1091–1095.
[9] B. Wu, E.Y. Chien, C.D. Mol, G. Fenalti, W. Liu, V. Katritch, R. Abagyan, A. Brooun, P.
Wells, F.C. Bi, D.J. Hamel, P. Kuhn, T.M. Handel, V. Cherezov, R.C. Stevens, Structures
of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists,
Science 330 (2010) 1066–1071.
[10] T. Shimamura, M. Shiroishi, S. Weyand, H. Tsujimoto, G. Winter, V. Katritch, R.
Abagyan, V. Cherezov, W. Liu, G.W. Han, T. Kobayashi, R.C. Stevens, S. Iwata,
Structure of the human histamine H1 receptor complex with doxepin, Nature 475
(2011) 65–70.
[11] K. Haga, A.C. Kruse, H. Asada, T. Yurugi-Kobayashi, M. Shiroishi, C. Zhang, W.I. Weis,
T. Okada, B.K. Kobilka, T. Haga, T. Kobayashi, Structure of the human M2 muscarinic
acetylcholine receptor bound to an antagonist, Nature 482 (2012) 547–551.
[12] M.A. Hanson, C.B. Roth, E. Jo, M.T. Grifﬁth, F.L. Scott, G. Reinhart, H. Desale, B.
Clemons, S.M. Cahalan, S.C. Schuerer, M.G. Sanna, G.W. Han, P. Kuhn, H. Rosen, R.
C. Stevens, Crystal structure of a lipid G protein-coupled receptor, Science 335
(2012) 851–855.
[13] A. Manglik, A.C. Kruse, T.S. Kobilka, F.S. Thian, J.M. Mathiesen, R.K. Sunahara, L.
Pardo,W.I.Weis, B.K. Kobilka, S. Granier, Crystal structure of themu-opioid receptor
bound to a morphinan antagonist, Nature 485 (2012) 321–326.
[14] J.F. White, N. Noinaj, Y. Shibata, J. Love, B. Kloss, F. Xu, J. Gvozdenovic-Jeremic, P.
Shah, J. Shiloach, C.G. Tate, R. Grisshammer, Structure of the agonist-bound
neurotensin receptor, Nature 490 (2012) 508–513.
[15] H. Wu, D. Wacker, M. Mileni, V. Katritch, G.W. Han, E. Vardy, W. Liu, A.A. Thompson,
X.P. Huang, F.I. Carroll, S.W. Mascarella, R.B. Westkaemper, P.D. Mosier, B.L. Roth, V.
Cherezov, R.C. Stevens, Structure of the human kappa-opioid receptor in complex
with JDTic, Nature 485 (2012) 327–332.
[16] C. Zhang, Y. Srinivasan, D.H. Arlow, J.J. Fung, D. Palmer, Y. Zheng, H.F. Green, A.
Pandey, R.O. Dror, D.E. Shaw, W.I. Weis, S.R. Coughlin, B.K. Kobilka, High-
resolution crystal structure of human protease-activated receptor 1, Nature 492
(2012) 387–392.
[17] K. Hollenstein, J. Kean, A. Bortolato, R.K. Cheng, A.S. Dore, A. Jazayeri, R.M. Cooke, M.
Weir, F.H. Marshall, Structure of class B GPCR corticotropin-releasing factor receptor
1, Nature 499 (2013) 438–443.
[18] F.Y. Siu,M. He, C. de Graaf, G.W. Han, D. Yang, Z. Zhang, C. Zhou, Q. Xu, D.Wacker, J.S.
Joseph, W. Liu, J. Lau, V. Cherezov, V. Katritch, M.W. Wang, R.C. Stevens, Structure of
the human glucagon class B G-protein-coupled receptor, Nature 499 (2013)
444–449.
[19] P. Egloff, M. Hillenbrand, C. Klenk, A. Batyuk, P. Heine, S. Balada, K. Schlinkmann, D.J.
Scott, M. Schütz, A. Plückthun, Structure of signaling-competent neurotensin
receptor 1 obtained by directed evolution in E. coli, Proc. Natl. Acad. Sci. U. S. A.
111 (2014) E655–E662.
[20] E. Chun, A.A. Thompson, W. Liu, C.B. Roth, M.T. Grifﬁth, V. Katritch, J. Kunken, F. Xu,
V. Cherezov, M.A. Hanson, R.C. Stevens, Fusion partner toolchest for the stabilization
and crystallization of G protein-coupled receptors, Structure 20 (2012) 967–976.
[21] D.M. Rosenbaum, V. Cherezov, M.A. Hanson, S.G. Rasmussen, F.S. Thian, T.S. Kobilka,
H.J. Choi, X.J. Yao, W.I. Weis, R.C. Stevens, B.K. Kobilka, GPCR engineering yields
high-resolution structural insights into beta2-adrenergic receptor function, Science
318 (2007) 1266–1273.
[22] J. Standfuss, G. Xie, P.C. Edwards, M. Burghammer, D.D. Oprian, G.F. Schertler, Crystal
structure of a thermally stable rhodopsin mutant, J. Mol. Biol. 372 (2007)
1179–1188.
[23] C.B. Roth, M.A. Hanson, R.C. Stevens, Stabilization of the human beta2-adrenergic
receptor TM4–TM3–TM5 helix interface by mutagenesis of Glu122(3.41), a critical
residue in GPCR structure, J. Mol. Biol. 376 (2008) 1305–1319.
[24] F. Magnani, Y. Shibata, M.J. Serrano-Vega, C.G. Tate, Co-evolving stability and
conformational homogeneity of the human adenosine A2a receptor, Proc. Natl.
Acad. Sci. U. S. A. 105 (2008) 10744–10749.[25] M.J. Serrano-Vega, F. Magnani, Y. Shibata, C.G. Tate, Conformational
thermostabilization of the beta1-adrenergic receptor in a detergent-resistant
form, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 877–882.
[26] Y. Shibata, J.F. White, M.J. Serrano-Vega, F. Magnani, A.L. Aloia, R. Grisshammer, C.G.
Tate, Thermostabilization of the neurotensin receptor NTS1, J. Mol. Biol. 390 (2009)
262–277.
[27] C.A. Sarkar, I. Dodevski, M. Kenig, S. Dudli, A.Mohr, E. Hermans, A. Plückthun, Direct-
ed evolution of a G protein-coupled receptor for expression, stability, and binding
selectivity, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 14808–14813.
[28] I. Dodevski, A. Plückthun, Evolution of three human GPCRs for higher expression
and stability, J. Mol. Biol. 408 (2011) 599–615.
[29] K.M. Schlinkmann, M. Hillenbrand, A. Rittner, M. Kunz, R. Strohner, A. Plückthun,
Maximizing detergent stability and functional expression of a GPCR by exhaustive
recombination and evolution, J. Mol. Biol. 422 (2012) 414–428.
[30] K.M. Schlinkmann, A. Honegger, E. Türeci, K.E. Robison, D. Lipovsek, A. Plückthun,
Critical features for biosynthesis, stability, and functionality of a G protein-coupled
receptor uncovered by all-versus-all mutations, Proc. Natl. Acad. Sci. U. S. A. 109
(2012) 9810–9815.
[31] D.J. Scott, A. Plückthun, Direct molecular evolution of detergent-stable G protein-
coupled receptors using polymer encapsulated cells, J. Mol. Biol. 425 (2013) 662–667.
[32] A.S. Dore, N. Robertson, J.C. Errey, I. Ng, K. Hollenstein, B. Tehan, E. Hurrell, K.
Bennett, M. Congreve, F. Magnani, C.G. Tate, M. Weir, F.H. Marshall, Structure of
the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC
and caffeine, Structure 19 (2011) 1283–1293.
[33] G. Lebon, T. Warne, P.C. Edwards, K. Bennett, C.J. Langmead, A.G. Leslie, C.G. Tate,
Agonist-bound adenosine A2A receptor structures reveal common features of
GPCR activation, Nature 474 (2011) 521–525.
[34] T. Warne, R. Moukhametzianov, J.G. Baker, R. Nehme, P.C. Edwards, A.G. Leslie, G.F.
Schertler, C.G. Tate, The structural basis for agonist and partial agonist action on a
beta(1)-adrenergic receptor, Nature 469 (2011) 241–244.
[35] J. Huang, S. Chen, J.J. Zhang, X.Y. Huang, Crystal structure of oligomeric beta(1)-
adrenergic G protein-coupled receptors in ligand-free basal state, Nat. Struct. Mol.
Biol. 20 (2013) 419–425.
[36] M. Congreve, R.L. Rich, D.G. Myszka, F. Figaroa, G. Siegal, F.H. Marshall, Fragment
screening of stabilized G-protein-coupled receptors using biophysical methods,
Methods Enzymol. 493 (2011) 115–136.
[37] J.A. Christopher, J. Brown, A.S. Dore, J.C. Errey, M. Koglin, F.H. Marshall, D.G. Myszka,
R.L. Rich, C.G. Tate, B. Tehan, T. Warne, M. Congreve, Biophysical fragment screening
of the beta1-adrenergic receptor: identiﬁcation of high afﬁnity arylpiperazine leads
using structure-based drug design, J. Med. Chem. 56 (2013) 3446–3455.
[38] J.D. Pedelacq, S. Cabantous, T. Tran, T.C. Terwilliger, G.S. Waldo, Engineering and
characterization of a superfolder green ﬂuorescent protein, Nat. Biotechnol. 24
(2006) 79–88.
[39] J. Tucker, R. Grisshammer, Puriﬁcation of a rat neurotensin receptor expressed in
Escherichia coli, Biochem. J. 317 (Pt 3) (1996) 891–899.
[40] R. Grisshammer, P. Averbeck, A.K. Sohal, Improved puriﬁcation of a rat neurotensin
receptor expressed in Escherichia coli, Biochem. Soc. Trans. 27 (1999) 899–903.
[41] P. Kitabgi, C. Poustis, C. Granier, J. Van Rietschoten, J. Rivier, J.L. Morgat, P. Freychet,
Neurotensin binding to extraneural and neural receptors: comparison with biologi-
cal activity and structure–activity relationships, Mol. Pharmacol. 18 (1980) 11–19.
[42] P. Kitabgi, C.Y. Kwan, J.E. Fox, J.P. Vincent, Characterization of neurotensin binding to
rat gastric smooth muscle receptor sites, Peptides 5 (1984) 917–923.
[43] D. Gully, B. Labeeuw, R. Boigegrain, F. Oury-Donat, A. Bachy, M. Poncelet, R.
Steinberg, M.F. Suaud-Chagny, V. Santucci, N. Vita, F. Pecceu, C. Labbe-Jullie, P.
Kitabgi, P. Soubrie, G. Le Fur, J.P. Maffrand, Biochemical and pharmacological activ-
ities of SR 142948A, a new potent neurotensin receptor antagonist, J. Pharmacol.
Exp. Ther. 280 (1997) 802–812.
[44] C. Labbe-Jullie, J.M. Botto, M.V. Mas, J. Chabry, J. Mazella, J.P. Vincent, D. Gully, J.P.
Maffrand, P. Kitabgi, [3H]SR 48692, the ﬁrst nonpeptide neurotensin antagonist
radioligand: characterization of binding properties and evidence for distinct agonist
and antagonist binding domains on the rat neurotensin receptor, Mol. Pharmacol.
47 (1995) 1050–1056.
[45] C. Labbe-Jullie, S. Barroso, D. Nicolas-Eteve, J.L. Reversat, J.M. Botto, J. Mazella, J.M.
Bernassau, P. Kitabgi, Mutagenesis and modeling of the neurotensin receptor
NTR1. Identiﬁcation of residues that are critical for binding SR 48692, a nonpeptide
neurotensin antagonist, J. Biol. Chem. 273 (1998) 16351–16357.
[46] S. Barroso, F. Richard, D. Nicolas-Etheve, P. Kitabgi, C. Labbe-Jullie, Constitutive
activation of the neurotensin receptor 1 by mutation of Phe(358) in Helix seven,
Br. J. Pharmacol. 135 (2002) 997–1002.
[47] Y. Shibata, J. Gvozdenovic-Jeremic, J. Love, B. Kloss, J.F. White, R. Grisshammer, C.G.
Tate, Optimising the combination of thermostabilising mutations in the neurotensin
receptor for structure determination, Biochim. Biophys. Acta 1828 (2013) 9.
[48] A. Zhukov, S.P. Andrews, J.C. Errey, N. Robertson, B. Tehan, J.S. Mason, F.H. Marshall,
M. Weir, M. Congreve, Biophysical mapping of the adenosine A2A receptor, J. Med.
Chem. 54 (2011) 4312–4323.
